Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC): results of a randomised multicentre trial

Multicentre Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Letrozole in Combination with Trastuzumab Is Superior to Letrozole Monotherapy as First Line Treatment in Patients with Hormone-Receptor-Positive, HER2- Positive Metastatic Breast Cancer (MBC) – Results of theeLEcTRATrial.

10.1158/0008-5472.sabcs-09-4094 ◽

2009 ◽

Cited By ~ 6

Author(s):

J. Huober ◽

P. Fasching ◽

S. Paepke ◽

E. Kubista ◽

M. Barsoum ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Hormone Receptor Positive ◽

Abstract P2-16-10: Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer

10.1158/0008-5472.sabcs13-p2-16-10 ◽

2013 ◽

Author(s):

EA Perez ◽

JM López-Vega ◽

L Del Mastro ◽

T Petit ◽

C Zamagni ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

First‐Line Treatment Patterns and Clinical Outcomes in Patients With HER2‐Positive and Hormone Receptor‐Positive Metastatic Breast Cancer From registHER

The Oncologist ◽

10.1634/theoncologist.2012-0414 ◽

2013 ◽

Vol 18 (5) ◽

pp. 501-510 ◽

Cited By ~ 37

Author(s):

Debu Tripathy ◽

Peter A. Kaufman ◽

Adam M. Brufsky ◽

Musa Mayer ◽

Marianne Ulcickas Yood ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Treatment Patterns ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Hormone Receptor Positive ◽

5081 Triple combination of 3-weekly trastuzumab (T) plus oral vinorelbine (VNR) and capecitabine (CAP) as first-line treatment in HER2-positive metastatic breast cancer (MBC): an active and well-tolerated regimen that allows patient compliance

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70973-5 ◽

2009 ◽

Vol 7 (2) ◽

pp. 285 ◽

Cited By ~ 2

Author(s):

R. Palumbo ◽

A. Bernardo ◽

M.R. Strada ◽

G. Poggi ◽

C. Teragni ◽

...

Keyword(s):

Breast Cancer ◽

Patient Compliance ◽

Metastatic Breast ◽

Line Treatment ◽

Triple Combination ◽

First Line ◽

Her2 Positive ◽

Oral Vinorelbine ◽

Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer

Cancer Research and Treatment ◽

10.4143/crt.2021.1103 ◽

2022 ◽

Author(s):

Yong-Pyo Lee ◽

Min-Sang Lee ◽

HongSik Kim ◽

Ji-Yeon Kim ◽

Jin-Seok Ahn ◽

...

Keyword(s):

Breast Cancer ◽

Real World ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Korean Patients ◽

Real World Evidence ◽

Capecitabine/trastuzumab for the first-line treatment of patients with HER2-positive metastatic breast cancer (MBC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.1139 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 1139-1139

Author(s):

A. Chan ◽

D. Yamamoto ◽

R. Bell

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Metastatic Breast Cancer with Hormone Receptor-positive and HER2-positive (SYSUCC-002)

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-21-3435 ◽

2021 ◽

pp. clincanres.3435.2021

Author(s):

Xin Hua ◽

Xi-wen Bi ◽

Jian-Li Zhao ◽

Yan-Xia Shi ◽

Ying Lin ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Hormone Receptor Positive ◽

Randomized phase III study of trastuzumab monotherapy followed by docetaxel and trastuzumab versus the combination of trastuzumab and docetaxel as first-line treatment in patients with HER2 positive metastatic breast cancer.

10.1158/0008-5472.sabcs-3132 ◽

2009 ◽

Cited By ~ 3

Author(s):

K Najagami ◽

K Inoue ◽

M Mizutani ◽

Y Hozumi ◽

Y Fujiwara ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Phase Iii Study ◽

Trastuzumab Monotherapy ◽

Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer

Annals of Oncology ◽

10.1093/annonc/mdt222 ◽

2013 ◽

Vol 24 (8) ◽

pp. 2005-2011 ◽

Cited By ~ 11

Author(s):

J. Crown ◽

M.J. Kennedy ◽

P. Tresca ◽

M. Marty ◽

M. Espie ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

2124 POSTER Triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer (MBC): latest results of an international phase II trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)70886-8 ◽

2007 ◽

Vol 5 (4) ◽

pp. 221-222

Author(s):

A. Chan ◽

V. Ganju ◽

D. Becquart ◽

P.F. Conte ◽

L. Petruzelka ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

Triple Combination ◽

First Line ◽

Her2 Positive ◽

Oral Vinorelbine ◽